leadf
logo-loader
viewQ BioMed Inc.

Q BioMed advancing its liver cancer treatment through the pipeline

Q BioMed Inc (OTCMKTS:QBIO) CEO Denis Corin tells Proactive the biotech will advance Uttroside-B in its portfolio and move it quickly towards monetization.

Corin says the efficacy of Uttroside-B, a potent saponin, was demonstrated in a preclinical study published in the November 2016 issue of Scientific Reports, which has shown great potential as a treatment for liver cancer.

Quick facts: Q BioMed Inc.

Price: 1.03 USD

OTCQB:QBIO
Market: OTCQB
Market Cap: $24.11 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Q BioMed Inc. named herein, including the promotion by the Company of Q BioMed Inc. in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Q BioMed gets US patent for its Uttrocide-B molecule as a potential liver...

Q BioMed Inc (OTCQB:QBIO) CEO Denis Corin tells Proactive it has received a US patent for its Uttrocide-B molecule as a potential liver cancer treatment. Corin says the company now has the exclusive rights to the technology through an agreement with the Rajiv Gandhi Centre for Biotechnology,...

2 weeks, 4 days ago

2 min read